High concentrations of adenosine in tumor microenvironments inhibit antitumor cytotoxic lymphocyte responses. Although T cells express inhibitory adenosine A 2A receptors (A 2A R) that suppress their activation and inhibit immune killing of tumors, a role for myeloid cell A 2A Rs in suppressing the immune response to tumors has yet to be investigated. In this study, we show that the growth of transplanted syngeneic B16F10 melanoma or Lewis lung carcinoma cells is slowed in Adora2a f/f -LysMCre þ/À mice, which selectively lack myeloid A 2A Rs. Reduced melanoma growth is associated with significant increases in MHCII and IL12 expression in tumor-associated macrophages and with >90% reductions in IL10 expression in tumorassociated macrophages, dendritic cells (DC), and Ly6C þ or Ly6G þ myeloid-derived suppressor cells (MDSC). 
Introduction
Many elements of myeloid cell, T-cell, and natural killer (NK) cell activation in the tumor environment are shaped by their interaction, for example, antigen presentation and communication through cytokines (1) . Immunosuppressive tumor microenvironments inhibit these interactions and facilitate immune system evasion by tumor cells. Tumor-associated macrophages and myeloid-derived suppressor cells (MDSC) are early responders to neoplastic growth. Hence, lymphocyte cytotoxicity and activation are shaped by the phenotypes of the macrophages they initially interact with. Tumor-associated macrophages are often polarized towards an anti-inflammatory/proangiogenic M2 phenotype rather than the tumoricidal M1 phenotype that produces high amounts of IL12 and MHCII to enhance antitumor T-cell responses (2) . Macrophage polarization is influenced by location within the tumor. Normoxic tumor areas are more likely to contain M1 macrophages while proangiogenic M2/M2-like macrophages preferentially reside in hypoxic areas (3) .
Solid tumor microenvironments are hypoxic, inflamed, and exhibit a high frequency of apoptotic cell death. Cells that are stressed by hypoxia or inflammation and apoptotic cells release ATP. Although extracellular ATP enhances immune cell chemotaxis and activation through engagement with P2 purinergic receptors, it is rapidly degraded to adenosine by ectonucleotidases. CD39, which converts ATP/ADP to AMP, is expressed on regulatory T cells and activated NK T cells and macrophages. CD73, which converts AMP to adenosine, is highly expressed by some tumors including ER À breast tumors, endothelial cells, regulatory T cells, and most B cells (4, 5) . Macrophages modulate their activation state by increasing the synthesis and secretion of ATP that in the tumor microenvironment is immunosuppressive due to its rapid catabolism into adenosine by CD39 and CD73 (6) . Therefore, solid tumor microenvironments favor the production high concentrations of adenosine that impairs antitumor T-cell responses (7, 8) .
Adenosine exerts its effects by engaging four subtypes of P1 purinergic or adenosine receptors: A 1 , A 2A , A 2B , and A 3 . A 2A R and A 2B R mRNA expression increases in activated macrophages (9) (10) (11) (12) (13) , and signaling through A 2A Rs inhibits the activation of macrophages by inflammatory stimuli and promotes remodeling to an M2-like phenotype (9, 14) . Prolonged A 2A R and A 2B R stimulation facilitates tissue-healing responses by stimulating the production of factors such as VEGF and IL6 that promote angiogenesis and fibrosis (9, 14, 15) . These findings suggest that adenosine plays an important dynamic role in shaping macrophage responses during acute and chronic injury.
There is growing evidence that even syngeneic tumors can evoke immune responses that can suppress or sometimes arrest tumor growth. Depletion of T cells prevented the rejection of certain highly immunogenic melanomas in A 2A R-deficient mice (7) . Increased metastasis due to high expression of CD73, which elevates adenosine, is prevented by blockade of either A 2A Rs or A 2B Rs, which increase NK cell activity (16, 17 
Materials and Methods

Cell lines, animals, and reagents
Animal experiments were approved by the Animal Care and Use Committee of the La Jolla Institute for Allergy & Immunology (La Jolla, CA). B16F10 cells stably expressing luciferase were obtained from Caliper Life Sciences and Lewis lung carcinoma (LLC) cells were obtained from the ATCC and cultured in R5F (RPMI1640 medium containing 10% heat-inactivated FBS, 2 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, 50 U/mL penicillin, 50 mg/mL streptomycin). The cell lines were tested and authenticated by the ATCC for post-freeze viability, growth properties, mycoplasma contamination, species contamination, and sterility. Cell lines from Caliper Life Sciences were tested for being pathogen free. Ovalbumin-expressing B16F10 cells were obtained and characterized as described in ref. 20 were provided by Dr. Stephen Schoenberger (La Jolla Institute for Allergy & Immunology, La Jolla, CA). Ovalbumin-and luciferaseexpressing B16F10 cells were obtained from Dr. Andreas Limmer (University of Bonn, Bonn, Germany) and Dr. Natalio Garbi (University of Bonn) through Dr. Gerhard Wingender (La Jolla Institute for Allergy and Immunology). All these cell lines were maintained according to ATCC guidelines. Authentication of luciferase-and/or ovalbumin-expressing cell lines was based on morphology, freeze-thaw viability, adherence, growth properties, mouse MHCI expression before and after IFNg treatment, cell surface expression of MHCI/Ova peptide complexes, and antigen-specific recognition of TRP2 or ovalbumin peptides by respective transgenic T cells. All cell lines were passaged less than 10 times after initial revival from frozen stocks. Cells were injected into mice after reaching 60% to 80% confluence. LysMCre mice (B6.129P2-Lyz2 tm1(cre)Ifo /J) were purchased from Jackson Laboratories. Adora2a f/f mice were generated as previously described (21) Fig. S1A ). In the same cell populations, A 2A R mRNA expression was reduced by 84% and 91% in macrophages and neutrophils, respectively ( Supplementary Fig. S1B ). Interestingly, A 2A R mRNA expression in peritoneal T cells was increased in mice with myeloidselective A 2A R deletion, probably as a consequence of APCmediated T-cell activation. SIINFEKL-loaded H2K b tetramers with human b2-microglobulin were provided by NIH Tetramer Core Facility and tetramerized using streptavidin-phycoerythrin conjugates from Invitrogen according to the instructions on NIH tetramer core facility website. SIINFEKL-loaded H2K b tetramers were used to detect ovalbumin-antigen-specific CD8 þ T cells. Yellow, blue, or aqua fluorescent reactive dyes were from Invitrogen. Fluorescent antibodies used in this study, their sources, and dilutions used are listed in Supplementary Table S1 . Depleting CD8a and NK1.1 antibodies were purchased from BioXCell.
Ex vivo tumor cell killing by macrophages Bone marrow-derived macrophages were prepared according to a protocol modified from Cekic and colleagues (22) . Briefly, femurs and tibiae from 8-to 12-week-old mice were collected and flushed twice with sterile Hank balanced salt solution. Bone morrow cells were cultured overnight in standard tissue culture plates in the presence of 10 ng/mL macrophage colony stimulating factor (M-CSF). Nonadherent cells from this initial culture were then transferred to low-attachment 6-well plates (Corning Life Sciences) in 4 mL R5F containing 30% L929 conditioned medium and 10 ng/mL M-CSF for 7 days, adding 1.5 mL fresh medium on days 3 and 5. Resulting macrophages were either prestimulated with 100 ng lipopolysaccharide (LPS; Invitrogen) or kept unstimulated for 24 hours before coincubating with B16F10 tumor cells (1:20 target to effector ratio) in 96-well round-bottom culture plates in the presence or absence of the A 2A R agonist CGS 21680 (1 mmol/L). 7AAD staining and CD45 staining was used to identify dead cells and myeloid cells, respectively.
Flow cytometry
Single-cell suspensions from indicated tissues were prepared by sequentially pressing cells through 100 mm and 40 mm cell strainers. After RBC lysis (Biolegend) cells were washed and resuspended in R10F, and counted in a Z2-Coulter particle counter (Beckman Coulter). Most dead cells were removed from tumor samples by Ficoll gradient centrifugation at 2,000 rpm (900 Â g) for 20 minutes at room temperature. Cells (3-5 Â 10 6 ) were preincubated for 10 minutes in 100 mL FACS buffer with antibody to block Fc receptors. Each sample tube received 100 mL fluorescently labeled antibody cocktail and was incubated for 30 minutes at 4 C in the dark. Cells were analyzed using an LSRII equipped with four lasers or an LSR Fortessa with five lasers and FACS Diva software (BD Biosciences). Live/dead fixable yellow, blue, or aqua fluorescent reactive dyes (Invitrogen) were used to exclude dead cells before analysis. Flow cytometry data were analyzed using FlowJo software (version 9.6.4, TreeStar Software Inc.).
Intracellular staining
For intracellular cytokine staining of T cells, single-cell suspensions of tumors in 7 mL R5F medium were layered on 2 mL Ficoll and centrifuged for 20 minutes at 2,000 rpm at room temperature. Spleen and Ficoll-enriched cell suspensions from tumors were restimulated with 10 ng/mL phorbol 12-myristate 13-acetate (PMA) and 100 ng/mL ionomycin (Sigma) or OVA 257-264 (SIINFEKL) peptide (Genscript USA) in the presence of Golgi Plug (eBioscience) for 5 hours at 37 C. Cells were fixed and permeabilized after surface staining and incubated for 25 minutes at 4 C in 100 mL permeabilization/washing buffer containing 1:100 fluorescently labeled anti-IFNg. After a subsequent wash, cells were resuspended in 350 mL FACS buffer. For intracellular cytokine staining of myeloid cells, cell suspensions from tumors were resuspended in FACS buffer containing Golgi Plug and kept in Golgi Plug throughout the surface staining procedure before fixation and permeabilization.
Tumor growth and metastasis
We injected 2 Â 10 5 LLC or 10 5 B16F10 melanoma cells expressing luciferase into the right flanks of Adora2a f/fLysMCre À/þ mice. Tumor volumes were measured using digital calipers and calculated as height Â width 2 /2. We also measured luciferase activity by using an IVIS 200 Bioluminescence Imager (Caliper Life Sciences) after intravenous injection of 1 mg D-luciferin (Caliper Life Sciences) in 100 mL PBS. This method was used to demonstrate that tumor size differences are not due to infiltration of host cells into the tumor mass. For metastasis analysis, 3 Â 10 5 B16F10 melanoma cells expressing luciferase and ovalbumin antigens were injected intravenously into the tail vain and luciferase activity was measured one and two weeks after the injection of cancer cells. After measuring luciferase activity, lungs were removed, photographed, and weighted to validate luciferase activity correlates with lung tumor mass. For in vivo depletion of CD8 þ T cells or NK cells, respectively, 200 mg anti-CD8a (clone (53-6.72) or anti-NK1.1 (PK136) antibodies were injected intraperitoneally four times at 5-day intervals, beginning a day before the subcutaneous injection of tumors. Cell depletion from spleen was verified by flow cytometry.
Results
Myeloid deletion of Adora2a inhibits solid tumor growth
To investigate cell-intrinsic effects of myeloid Adora2a expression on APC function and antitumor immune responses we generated mice with floxed Adora2a (21) and crossed these to mice that express Cre recombinase under control of the LysM promoter to create Adora2a f/f -LysMCre þ/À mice with myeloid-selective A 2A R deletion. These mice and Cre À littermate controls were injected with syngeneic tumors. Myeloid deletion of Adora2a significantly reduced the growth rates of B16F10 melanomas and LLCs (Fig. 1A) . In the case of B16F10 melanomas, tumor growth measured with calipers ( Fig. 1A ) was confirmed by luciferase activity (Fig. 1B) .
Myeloid deletion of Adora2a increases macrophage activation and effector function in tumors
LysMCre excises floxed target genes in granulocytes including macrophages and to a lesser extent in myeloid DCs. We measured the number and activation states of myeloid cell populations in tumors using the gating strategy shown in Fig. 2A (left) . Deletion of Adora2a did not significantly change myeloid cell density in tumors ( IL10 mRNA is also reduced in sorted tumor-associated macrophages and DCs lacking A 2A Rs (Fig. 3D) . Overall, these data indicate that myeloid-selective deletion of A 2A Rs favors M1 polarization of macrophages and substantially reduces anti-inflammatory IL10 production by myeloid cell populations.
Myeloid deletion of A2ARs increases the number and activation of cytotoxic lymphocytes A 2A R signaling promotes tumor growth by inhibiting the activation of T cells and NK cells (7, 16, 19) . The contribution of myeloid cell A 2A R signaling to these processes is not known. LysMCre-mediated deletion of Adora2a f/f significantly increased the proportion (Fig. 4A) and density (Fig. 4B ) of tumor-associated cytotoxic lymphocytes and their surface expression of CD44 (Fig. 4C and D from Adora2a f/f -LysMCre À/À littermate controls (Fig. 6) . Overall, our results suggest that myeloid expression of A 2A R is important in indirect adenosine-mediated suppression of T cells and NK cells.
Myeloid deletion of Adora2a inhibits tumor metastasis
Metastasis is a hallmark of late-stage tumors that is frequently responsible for cancer-associated deaths. Therefore, we determined whether the reduction in the growth of melanomas after myeloid deletion of Adora2a is associated with reduced lung metastases following intravenous transfer of B16F10 melanoma cells (expressing luciferase for in vivo imaging and ovalbumin as model antigen) into Adora2a f/fLysMCre þ/À mice or Cre À littermate controls. Myeloid deletion of Adora2a reduced tumor-associated luciferase expression in the lungs over a two-week period by 10-to 30-fold (Fig. 7A ). This was associated with reduced tumor mass in the lungs (Fig.  7B ) and reduced lung weight (Fig. 7C) . These data indicate that myeloid cells are important targets of A 2A R-mediated enhanced tumor metastasis.
7-AAD
A 2A R and A 2B R blockade significantly reduced the metastasis of CD73-expressing tumors through enhanced NK cell activation (8, 16) . Previous studies have focused on the role of CD8 þ T cells in reducing metastasis upon A 2A R deletion (15, 16, 19) . We observed a significant increase in the numbers of lung-associated NK cells but not CD8 Supplementary Fig. S2 ).
However, numbers of antigen-specific CD8 þ T cells were also increased ( Supplementary Fig. S2 ). Both NK and CD8 þ T cells had higher expression of CD44 in lung after tumor inoculation ( Supplementary Fig. S2 ). These results suggest that both NK and CD8 þ T cells may be important for reducing metastasis of tumors to the lung and their activity is strongly regulated by myeloid cell A 2A R expression. Overall, these data suggest that myeloid cell A 2A Rs contribute importantly to adenosine-mediated suppression of T cells and NK cells in tumors.
Discussion
Cancer immunotherapy is emerging as a treatment option for patients with late-stage tumors (23, 24) . Modulating tumor microenvironments by antagonizing tumor-associated negative immune regulators such as PD-1, TGFb, or adenosine has been viewed as an attractive treatment strategy (25, 26) . In the current study, we found that myeloidselective deletion of Adora2a slowed tumor growth and significantly increased activation markers, IL12 and MHCII, on macrophages without affecting ex vivo cytotoxicity. Myeloid-selective deletion of the A2AR also decreased >90% IL10 production by tumor-associated macrophages, DCs, and MDSCs. This was associated with increased NK and CD8 þ T-cell numbers, CD44 expression, and T-cell IFNg production in the tumor.
Deletion of A 2A Rs from T cells causes T-cell activation, but reduces T-cell survival and memory cell differentiation in the solid tumor environment (27) . Consequently, selective deletion of T-cell Adora2a sometimes reduces T-cell numbers and enhances the growth rate of large solid tumors. Here, we show that sparing A 2A Rs on T cells while depleting them from myeloid cells indirectly enhances tumor killing by increasing T-cell and NK cell activation in tumors. In previous studies, limiting adenosine production through inhibition or deletion of CD73 also enhanced solid tumor killing through activation of adaptive immune responses and through reduction in A 2A R signaling in hematopoietic cells (14, 16, (28) (29) (30) . The current study suggests that myeloidselective blockade of A 2A R signaling may be preferential to global or T-cell-selective blockade that can trigger T cell apoptosis in tumors. Moreover, enhanced APC activity likely mediates some of the effects of CD73 deletion. CD73 deletion limits, but does not abolish, adenosine production in tumor F4/80 (1) CD11c (2) Ly6C ( Adenosine may have multiple cellular targets and engage both A 2A Rs and A 2B Rs to promote metastasis. Reduced A 2B R activation was primarily responsible for decreased lung metastasis of breast tumor cells after CD73 blockade (17) . Both A 2A R and A 2B R signaling were shown to promote metastasis of tumors highly expressing CD73 (16, 17) . A 2B R stimulation in tumor cells promotes metastasis by reducing cell-to-cell contact (31, 32) , and influences endothelial cells and APCs to further promote metastasis (16, 31, 33, 34) . A 2A R signaling in NK cells and T cells is thought to promote tumor growth and metastasis by directly inhibiting their cytotoxic activity (16, 17, 31, 33) . To our knowledge, the current study is the first to show that myeloid A 2A R signaling strongly suppress NK and T-cell responses in lungs and promotes lung metastasis of B16 melanoma cells. Therefore, some of the effects of adenosine-mediated immune suppression on NK cells and T cells described in previous studies can be attributed to indirect effects of A 2A R signaling in myeloid cells.
Macrophages can be polarized to different phenotypes that have opposing functions. Endogenous TLR ligands released from dead cells and cytokines such as IFNg produced by NK cells and T cells remodel macrophages into antitumor effectors (2) . These effector macrophages produce IL12 to enhance T-cell and NK cell activation and proliferation in tumors (35, 36) . Effector macrophages can also cross present tumor-associated antigens to CD8 þ T cells (37) (38) (39) . Adenosine polarizes macrophages into a tissue healing/tumor-promoting phenotype. These M2-like macrophages produce anti-inflammatory IL10 to suppress immune cells and VEGF to support angiogenesis (9, 40) . Therefore, potential therapies targeting macrophages may improve our arsenal of antitumor agents.
The current study provides evidence indicating that macrophage A 2A Rs have great potential as therapeutic targets. It is important to note that Adora2a is expressed not only by macrophages, but also by other immune cell types, such as NK cells and DCs, which have only low levels of LysM promoter activity. It is well established that A 2A R stimulation on DCs and NK cells regulate their activation (14) . Therefore, additional studies are needed to elucidate how NK or DC-specific deletions of Adora2a will affect antitumor immune responses. Our findings demonstrate clearly that myeloid activation by targeted A2AR deletion is sufficient to strongly inhibit tumor growth and metastasis. These findings suggest that myeloid cell activation by targeted adenosine receptor blockade or by other means may be useful approaches for enhancing tumor killing by immunotherapy. Data were analyzed using the Student t test.
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